CD37 and neoplasm: Follow-up cohort studies in two responding PDX models (Ly12638 and Ly13005) confirmed potent, dose-dependent anti-tumor activity of DuoHexaBody-CD37 at doses as low as 1 mg/kg (Fig. 6c).